Physician profile
Miranda Tedder
NPI 1023650868
$15,267.61
in general payments reported to CMS, 2019-2025
36 companies · $789 in 2025
The $789 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,358 · 2022: $4,069 · 2023: $5,500 · 2024: $1,551 · 2025: $789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,841.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,840.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,374.68 | 2021-2025 | |
| Novo Nordisk INC | $2,099.62 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,793.36 | 2021-2025 | Farxiga, Airsupra |
| Biohaven Pharmaceuticals, INC. | $1,098.03 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,005.49 | 2022-2025 | |
| Lilly USA, LLC | $977.34 | 2021-2024 | Mounjaro, Emgality, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $637.35 | 2021-2024 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $607.54 | 2022-2025 | Caplyta |
| Pfizer INC. | $549.09 | 2022-2024 | |
| Alkermes, INC. | $438.32 | 2022-2024 | Aristada, Lybalvi |
| Glaxosmithkline, LLC. | $433.88 | 2022-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Esperion Therapeutics, INC. | $418.38 | 2021-2022 | |
| Antares Pharma, INC. | $294.42 | 2022-2023 | Tlando, Xyosted, Nocdurna |
| Idorsia Pharmaceuticals US INC | $266.33 | 2022-2023 | Quviviq |
| Amgen INC. | $241.86 | 2022-2024 | Prolia, Evenity, Repatha |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $241.80 | 2022-2024 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $204.92 | 2023 | Rexulti |
| Tris Pharma INC | $169.39 | 2023-2024 | Dyanavel Xr, Quillichew Er, Quillivant |
| Biohaven Pharmaceutical Holding Company LTD. | $164.08 | 2022 | |
| Edwards Lifesciences Corporation | $154.62 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Supernus Pharmaceuticals, INC. | $149.05 | 2023-2024 | Qelbree, Qelbree |
| Astellas Pharma US INC | $140.00 | 2023 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $130.33 | 2023 | Cologuard Collection Kit |
| Vanda Pharmaceuticals INC. | $119.70 | 2025 | Fanapt |
| Axsome Therapeutics, INC. | $92.76 | 2023-2024 | Auvelity |
| Neurocrine Biosciences, INC. | $87.52 | 2023-2024 | Ingrezza, Ongentys |
| Lundbeck LLC | $83.23 | 2023-2024 | Rexulti |
| Ironwood Pharmaceuticals, INC | $75.94 | 2022-2023 | Linzess |
| Ironshore Pharmaceuticals INC. | $51.94 | 2022-2023 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $42.12 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.45 | 2023 | Trintellix |
| Novartis Pharmaceuticals Corporation | $30.17 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $19.35 | 2023 | Voquezna |
| Cranial Technologies, INC | $16.56 | 2023 | Doc Band |
| Dynavax Technologies Corporation | $14.60 | 2022 | |
| Sanofi-Aventis U.S. LLC | $12.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miranda Tedder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.